Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Hunter Immunology

2003 FOUNDED
M&A STATUS
M&A LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

Developer of medicinal drugs intended to treat patient suffering from chronic obstructive pulmonary disease (COPD).

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Acquirer
Probiomics
Primary Office
  • Avalon Parade 61
  • Sydney, New South Wales 2107
  • Australia

Hunter Immunology Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Hunter Immunology‘s full profile, request access.

Request full access to PitchBook

Hunter Immunology Executive Team (1)

Name Title Board
Seat
Contact
Info
David Radford Chief Executive Officer